NeuroSense Secures November 10 Nasdaq Hearing Date; Bid-Price Compliance Regained
NRSN is trading near its 52-week low of $3.28 (6.1% above the low) on light trading volume (0.3× avg).
Summary
NeuroSense announced a November 10, 2026 Nasdaq hearing date to appeal its delisting determination, confirmed it has regained bid-price compliance, and outlined near-term regulatory and funding milestones for PrimeC.
Key Events · Legal and Risk Events · NRSN
-
Nasdaq Hearing Scheduled
Hearing before the Nasdaq Hearings Panel set for November 10, 2026, following timely appeal of the October 1, 2026 Staff Delisting Determination.
-
Bid-Price Compliance Regained
Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement; only remaining deficiency is the $35 million minimum market value of listed securities under Rule 5550(b)(2).
-
Compliance Plan to Be Presented
Company intends to present a plan to meet the $35 million market value requirement or the alternative $2.5 million stockholders' equity standard under Rule 5550(b)(1), including balance-sheet strengthening measures and timelines.
-
Exception Period Requested
Company will request an exception period of up to 180 days from the October 1 Staff Determination; no assurance the Panel will grant it.
Analysis · NRSN · Life Sciences
A concrete date — November 10, 2026 — is now set for NeuroSense to argue for continued Nasdaq listing after the October 1 delisting determination. The company has already regained the $1.00 minimum bid price, leaving only the $35 million market value requirement (or the alternative $2.5 million stockholders' equity standard) to address. With a market cap of roughly $6.6 million, the equity standard is the more realistic path, and the company says it will present balance-sheet strengthening measures with timelines. The appeal stays delisting, so shares keep trading pending the Panel's decision. Separately, the company reaffirmed a December 2026 Health Canada New Drug Submission for PrimeC and a Q1 2027 decision on non-dilutive grant funding for the Phase 3 PARAGON trial — milestones that could reduce reliance on equity financing at a time when cash is critically low.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NRSN was trading at $3.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6M. The 52-week trading range was $3.28 to $26.64. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.